Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
April 27, 2023 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, April 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
April 12, 2023 09:00 ET
|
Ceapro Inc.
– 2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year – Net profit after tax of...
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
March 23, 2023 09:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, March 23, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
March 08, 2023 08:45 ET
|
Ceapro Inc.
– Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on angiogenesis, wound healing and tissue...
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
February 21, 2023 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Announces Grant of Stock Options
January 04, 2023 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
December 22, 2022 09:00 ET
|
Ceapro Inc.
- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the Montreal Heart Institute led by MHI’s Montreal Health Innovations...
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 09, 2022 09:00 ET
|
Ceapro Inc.
– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology – Q3 2022 sales of $3,845,000 vs $4,523,000 in Q3 2021; YTD sales...
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets
November 07, 2022 09:00 ET
|
Ceapro Inc.
PGX processing unit to be installed at Agri-Food Discovery Place of University of AlbertaAlginate and yeast beta glucan to be the first bio actives to be processed at this location EDMONTON,...